E-viri
PDF
Recenzirano
Odprti dostop
-
Wirth, Lori J; Sherman, Eric; Robinson, Bruce; Solomon, Benjamin; Kang, Hyunseok; Lorch, Jochen; Worden, Francis; Brose, Marcia; Patel, Jyoti; Leboulleux, Sophie; Godbert, Yann; Barlesi, Fabrice; Morris, John C; Owonikoko, Taofeek K; Tan, Daniel S.W; Gautschi, Oliver; Weiss, Jared; de la Fouchardière, Christelle; Burkard, Mark E; Laskin, Janessa; Taylor, Matthew H; Kroiss, Matthias; Medioni, Jacques; Goldman, Jonathan W; Bauer, Todd M; Levy, Benjamin; Zhu, Viola W; Lakhani, Nehal; Moreno, Victor; Ebata, Kevin; Nguyen, Michele; Heirich, Dana; Zhu, Edward Y; Huang, Xin; Yang, Luxi; Kherani, Jennifer; Rothenberg, S. Michael; Drilon, Alexander; Subbiah, Vivek; Shah, Manisha H; Cabanillas, Maria E
New England journal of medicine/The New England journal of medicine, 08/2020, Letnik: 383, Številka: 9Journal Article
Medullary thyroid cancer often develops in patients with somatic or germline mutations in RET . Selpercatinib is a novel RET inhibitor. In a phase 1–2 trial, a response to selpercatinib occurred in 38 of 55 previously treated patients (69%) and in 64 of 88 previously untreated patients (73%). Toxic effects were mainly low grade.
